1. Home
  2. VOC vs BOLD Comparison

VOC vs BOLD Comparison

Compare VOC & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VOC

VOC Energy Trust Units of Beneficial Interest

HOLD

Current Price

$3.48

Market Cap

58.6M

Sector

Energy

ML Signal

HOLD

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$1.51

Market Cap

36.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
VOC
BOLD
Founded
2010
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Sector
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
58.6M
36.5M
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
VOC
BOLD
Price
$3.48
$1.51
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.00
AVG Volume (30 Days)
107.3K
404.0K
Earning Date
01-01-0001
05-08-2026
Dividend Yield
12.72%
N/A
EPS Growth
N/A
32.47
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$6.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.60
$0.96
52 Week High
$3.84
$1.78

Technical Indicators

Market Signals
Indicator
VOC
BOLD
Relative Strength Index (RSI) 54.20 62.76
Support Level $2.72 $1.08
Resistance Level $3.78 $1.55
Average True Range (ATR) 0.14 0.09
MACD 0.01 0.03
Stochastic Oscillator 81.58 69.23

Price Performance

Historical Comparison
VOC
BOLD

About VOC VOC Energy Trust Units of Beneficial Interest

VOC Energy Trust is a statutory trust. It is created to acquire and hold a term net profits interest for the benefit of the Trust unitholders. The underlying properties include VOC Brazos' net interests which are located in the states of Kansas and Texas. The trust is entitled to receive the net proceeds from the sale of production of oil and natural gas attributable to the underlying properties. The business and affairs of the Trust are managed by the Trustee, and neither VOC Brazos nor any of its affiliates has the ability to manage or influence the operations of the Trust.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: